Number and proportion of admissions with Escherichia coli antibiotic resistance and number and proportion of admissions with a multidrug-resistant organism
| Antibiotic | Admissions with E. coli antibiotic resistance | P value | |
| 2008–2010 N (%) | 2015–2017 N (%) | ||
| Augmentin | 20 (16.5) | 41 (17.5) | 0.810 |
| Ceftriaxone | 4 (3.5) | 24 (10.3) | 0.029 |
| Ciprofloxacin | 4 (3.4) | 32 (13.8) | 0.003 |
| Gentamicin | 3 (2.5) | 21 (9.0) | 0.021 |
| Piptaz | 2 (1.9) | 15 (6.4) | 0.076 |
| Timentin | 12 (10.1) | 91 (39.6) | <0.001 |
| Cefotaxime | 11 (9.8) | 46 (19.7) | 0.020 |
| Co trimoxazole | 28 (23.1) | 60 (25.8) | 0.590 |
| Meropenem | 0 (0.0) | 2 (0.9) | 0.310 |
| MDR Bacteria | Admissions with MDR bacteria grown | P value | |
| 2008–2010 N (%) | 2015–2017 N (%) | ||
| MRSA | 11 (1.6) | 23 (2.0) | 0.610 |
| Escherichia coli (ESBL) | 2 (0.3) | 19 (1.6) | 0.010 |
| Enterococcus faecium (VRE) | 2 (0.3) | 6 (0.5) | 0.500 |
| Klebsiella pneumoniae (ESBL) | 1 (0.1) | 5 (0.4) | 0.310 |
| Escherichia coli CPE | 0 (0.0) | 1 (0.1) | 0.450 |
| Total MDR bacteria | 16 (2.3) | 54 (4.6) | 0.015 |
CPE, Carbapenemase-producing Enterobacterales; ESBL, Extended spectrum beta-lactamase; MDR, multidrug resistance; MRSA, Methicillin-resistant Staphylococcus aureus; VRE, Vancomycin-resistant enterococci.